Functional model insights
ICON Strategic Solutions provide insights on customised FSP models to enable the most flexible and efficient operating models for Sponsors.
Whitepaper: How investments in supply of CRAs is better than competing with the demand for CRAs
In this whitepaper, ICON’s experts address our commitment to four main objectives to reducing the CRA drought.
Download the whitepaperWhitepaper: The evolution of FSP, not just for large pharma
For mid-size pharma, CRO and FSP models may evolve as the company grows. This either/or decision often means switching models by switching suppliers. By harnessing the ‘Embedded Blended’ model, all sponsors can benefit from a synchronised outsourcing strategy.
Download the whitepaperWhitepaper: Clinical trials in Japan: An enterprise growth and management strategy
Presenting a unique approach to evolve the traditional local clinical development model in Japan, while lowering costs, improving productivity, and potentially accelerating drug approval timelines.
Download the whitepaperMedia articles
Media article: Redefining CRO sourcing model terminology to optimise outsourcing strategies
ICON is currently engaging with the Tufts CSDD - with input and in collaboration with ICON’s biopharmaceutical company Partners of Choice (PoC) - and invites input into a proposed new taxonomy and framework to redefine CRO sourcing model terminology.
Media article: A blended solution – how midsize pharmaceutical and biotech companies can optimise the delivery of their clinical trials
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid-size pharmaceutical and biotech companies.
Media article: Embedded blended solutions
John Barry and Brian Swindley offer their insights on the options available to pharma companies when delivering their clinical trial portfolios.
Media article: A golden opportunity but not a silver bullet
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked. (PDF)
Blogs
Blog: Redefining sourcing model terminology
As clinical development services and outsourcing models have become more complex, we have outgrown old definitions these models. This blog explores the new framework for defining CRO sourcing models and explains its importance.
Blog: Global outsourcing strategies
As the market for outsourcing continues to grow, so too have the types of outsourcing models available to sponsors.
Blog: How joint venture models can boost Japan’s pharmaceutical industry
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.
Strategic Solutions at ICON
ICON offers a range of FSP models that can be customised to deliver the most efficient operating model for your organisation. We have deployed FSP solutions across all major functions from clinical monitoring and project management through data management, statistical programming and beyond.
Read more